Literature DB >> 10800714

Cross-species comparison of in vivo reporter gene expression after recombinant adeno-associated virus-mediated retinal transduction.

J Bennett1, V Anand, G M Acland, A M Maguire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10800714     DOI： 10.1016/s0076-6879(00)16762-x

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  10 in total

1.  Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.

Authors:  Defne Amado; Federico Mingozzi; Daniel Hui; Jeannette L Bennicelli; Zhangyong Wei; Yifeng Chen; Erin Bote; Rebecca L Grant; Jeffrey A Golden; Kristina Narfstrom; Nasreen A Syed; Stephen E Orlin; Katherine A High; Albert M Maguire; Jean Bennett
Journal:  Sci Transl Med       Date:  2010-03-03       Impact factor: 17.956

Review 2.  The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.

Authors:  Eric A Pierce; Jean Bennett
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

3.  My career path for developing gene therapy for blinding diseases: the importance of mentors, collaborators, and opportunities.

Authors:  Jean Bennett
Journal:  Hum Gene Ther       Date:  2014-08       Impact factor: 5.695

Review 4.  Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork.

Authors:  Iok-Hou Pang; J Cameron Millar; Abbot F Clark
Journal:  Exp Eye Res       Date:  2015-05-27       Impact factor: 3.467

Review 5.  Subretinal injection in mice to study retinal physiology and disease.

Authors:  Peirong Huang; Siddharth Narendran; Felipe Pereira; Shinichi Fukuda; Yosuke Nagasaka; Ivana Apicella; Praveen Yerramothu; Kenneth M Marion; Xiaoyu Cai; Srinivas R Sadda; Bradley D Gelfand; Jayakrishna Ambati
Journal:  Nat Protoc       Date:  2022-04-13       Impact factor: 13.491

6.  Restoration of Vision and Retinal Responses After Adeno-Associated Virus-Mediated Optogenetic Therapy in Blind Dogs.

Authors:  Sergei Nikonov; Puya Aravand; Arkady Lyubarsky; Roman Nikonov; Angela J Luo; Zhangyong Wei; Albert M Maguire; Nicholas T Phelps; Ivan Shpylchak; Keirnan Willett; Tomas S Aleman; Rachel M Huckfeldt; Pavitra S Ramachandran; Jean Bennett
Journal:  Transl Vis Sci Technol       Date:  2022-05-02       Impact factor: 3.048

7.  Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.

Authors:  Jeannette Bennicelli; John Fraser Wright; Andras Komaromy; Jonathan B Jacobs; Bernd Hauck; Olga Zelenaia; Federico Mingozzi; Daniel Hui; Daniel Chung; Tonia S Rex; Zhangyong Wei; Guang Qu; Shangzhen Zhou; Caroline Zeiss; Valder R Arruda; Gregory M Acland; Lou F Dell'Osso; Katherine A High; Albert M Maguire; Jean Bennett
Journal:  Mol Ther       Date:  2008-01-22       Impact factor: 11.454

Review 8.  An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.

Authors:  Wei Chiu; Ting-Yi Lin; Yun-Chia Chang; Henkie Isahwan-Ahmad Mulyadi Lai; Shen-Che Lin; Chun Ma; Aliaksandr A Yarmishyn; Shiuan-Chen Lin; Kao-Jung Chang; Yu-Bai Chou; Chih-Chien Hsu; Tai-Chi Lin; Shih-Jen Chen; Yueh Chien; Yi-Ping Yang; De-Kuang Hwang
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

9.  AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury.

Authors:  J M K Kwong; L Gu; N Nassiri; V Bekerman; R Kumar-Singh; K D Rhee; X-J Yang; W W Hauswirth; J Caprioli; N Piri
Journal:  Gene Ther       Date:  2014-11-27       Impact factor: 5.250

10.  Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.

Authors:  Wensheng Li; Fansheng Kong; Xia Li; Xufeng Dai; Xiaoqiang Liu; Qinxiang Zheng; Ronghan Wu; Xiangtian Zhou; Fan Lü; Bo Chang; Qiuhong Li; William W Hauswirth; Jia Qu; Ji-Jing Pang
Journal:  Mol Vis       Date:  2009-02-06       Impact factor: 2.367
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.